Edition:
United States

MiMedx Group Inc (MDXG.OQ)

MDXG.OQ on NASDAQ Stock Exchange Capital Market

8.24USD
4:00pm EDT
Change (% chg)

$0.81 (+10.90%)
Prev Close
$7.43
Open
$7.40
Day's High
$8.52
Day's Low
$7.40
Volume
1,041,966
Avg. Vol
870,253
52-wk High
$18.24
52-wk Low
$6.05

Chart for

About

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical,... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $1,364.26
Shares Outstanding(Mil.): 112.47
Dividend: --
Yield (%): --

Financials

  MDXG.OQ Industry Sector
P/E (TTM): 65.63 32.19 32.74
EPS (TTM): 0.18 -- --
ROI: 14.78 13.89 14.38
ROE: 15.77 16.72 16.07

BRIEF-MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of Amniofix® Injectable For Treatment Of Osteoarthritis Of The Knee

* MIMEDX ENROLLS FIRST PATIENT IN ITS PHASE 2B CLINICAL TRIAL OF RMAT DESIGNATED AMNIOFIX® INJECTABLE FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE Source text for Eikon: Further company coverage:

Mar 28 2018

BRIEF-Mimedx Reports Positive Results From Phase 2B Clinical Trial Of Amniofix Injectable

* MIMEDX REPORTS POSITIVE PAIN AND FOOT FUNCTION RESULTS FROM PHASE 2B CLINICAL TRIAL OF AMNIOFIX® INJECTABLE IN THE TREATMENT OF PLANTAR FASCIITIS

Mar 26 2018

BRIEF-MiMedx Says "Confident" in Q1 Rev Guidance, Discloses DoJ Investigation

* MIMEDX ANNOUNCES EXPECTATION TO EXCEED THE $92 MILLION TOP END OF FIRST QUARTER REVENUE GUIDANCE

Mar 15 2018

BRIEF-Mimedx's Amniofix Injectable Granted RMAT Designation By FDA

* AMNIOFIX INJECTABLE GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION BY THE FDA FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE

Mar 09 2018

BRIEF-Mimedx Group Files For Non-Timely 10-K - SEC Filing

* MIMEDX - NOT ABLE TO PROVIDE QUANTITATIVE DESCRIPTION OF CHANGES IN RESULTS BETWEEN 2017, PRIOR PERIODS UNTIL AUDIT COMMITTEE COMPLETES INVESTIGATION Source text (http://bit.ly/2t9DPzh) Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 02 2018

U.S. Justice Department probing MiMedx's business practices: Bloomberg

Regenerative medicine maker MiMedx Group Inc is under federal investigation related to two business practices, Bloomberg reported on Monday, citing people familiar with the matter.

Feb 26 2018

U.S. Justice Dept probing MiMedx's business practices - Bloomberg

Feb 26 Regenerative medicine maker MiMedx Group Inc is under federal investigation related to two business practices, Bloomberg reported on Monday, citing people familiar with the matter.

Feb 26 2018

BRIEF-Mimedx Comments On Magistrate Recommendation In Co's Lawsuit Against Short Sellers

* MIMEDX COMMENTS ON MAGISTRATE RECOMMENDATION IN THE COMPANY'S LAWSUIT AGAINST SHORT SELLERS

Jan 18 2018

BRIEF-Mimedx Announces First Patients Have Been Enrolled In The Phase 3 Clinical Trial Of Amniofix

* MIMEDX ANNOUNCES FIRST PATIENTS HAVE BEEN ENROLLED IN THE PHASE 3 CLINICAL TRIAL OF AMNIOFIX® INJECTABLE IN PATIENTS WITH RECALCITRANT PLANTAR FASCIITIS PAIN

Jan 16 2018

BRIEF-Mimedx Settles Patent Infringement Lawsuit

* MIMEDX - SUCCESSFULLY SETTLED CO'S PATENT INFRINGEMENT LAWSUIT AGAINST MUSCULOSKELETAL TRANSPLANT FOUNDATION, MEDLINE INDUSTRIES, LIVENTA BIOSCIENCE

Jan 11 2018

Competitors

  Price Chg
Shire PLC (SHP.L) 3,820.00 -110.00
Shire PLC (3159084.L) -- --
Smith & Nephew plc (SN.L) 1,365.00 -12.50

Earnings vs. Estimates